Skip to content

N/A - iodine rct

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003781-42-GB
Enrollment
44
Registered
2005-08-22
Start date
2005-09-21
Completion date
Unknown
Last updated
2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient hypothyroxinanaemia

Interventions

Product Name: Sodium iodide Injection BP 2004 Product Code: non-proprietary Pharmaceutical Form: Oral solution INN or Proposed INN: Sodium iodide CAS Number: 7681-82-5 Concentration unit: µg/ml microg

Sponsors

University of Dundee
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Infants born ==65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Infants born > 30 weeks gestation. Mothers and infants will be excluded from the study if they are known to be viral hepatitis/HIV positive, have problmes giving consent because of mental illness or communication difficulties. Infants with serious congential anomaly will be excluded.

Design outcomes

Primary

MeasureTime frame
Main Objective: 1. We aim to determine whether enteral supplementation with iodine is effective in promoting a positive iodine balance in extreme preterm infants who are parenterally fed. 2. To determine the efficacy of the oral versus the nasogastric route of iodine supplementation.;Secondary Objective: None;Primary end point(s): Iodine balance at postnatal days 7, 14, 28

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026